Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KRYS Stock Forecast 2026-2027
$247.26
Current Price
$7.23B
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KRYS Price Targets
+50.0%
To High Target of $371.00
+25.4%
To Median Target of $310.00
-2.5%
To Low Target of $241.00
KRYS Price Momentum
-2.5%
1 Week Change
-10.6%
1 Month Change
+37.8%
1 Year Change
+0.3%
Year-to-Date Change
-17.1%
From 52W High of $298.30
+101.4%
From 52W Low of $122.80
📊 TOP ANALYST CALLS
Did KRYS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Krystal Biotech is one of their latest high-conviction picks.
Latest KRYS Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, KRYS has a bullish consensus with a median price target of $310.00 (ranging from $241.00 to $371.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $247.26, the median forecast implies a 25.4% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yigal Nochomovitz at Citigroup, projecting a 50.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KRYS Analyst Ratings
10
Buy
0
Hold
0
Sell
KRYS Price Target Range
Low
$241.00
Average
$310.00
High
$371.00
Current: $247.26
Latest KRYS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KRYS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 25, 2026 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $284.00 |
| Feb 18, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $323.00 |
| Feb 18, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $371.00 |
| Feb 17, 2026 | Jefferies | Roger Song | Buy | Maintains | $371.00 |
| Feb 2, 2026 | Goldman Sachs | Andrea Tan | Buy | Maintains | $327.00 |
| Jan 22, 2026 | B of A Securities | Alec Stranahan | Buy | Maintains | $318.00 |
| Jan 12, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $336.00 |
| Jan 9, 2026 | TD Cowen | Ritu Baral | Buy | Maintains | $306.00 |
| Jan 9, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $310.00 |
| Jan 9, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $320.00 |
| Jan 6, 2026 | Citigroup | Yigal Nochomovitz | Buy | Upgrade | $309.00 |
| Nov 4, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $220.00 |
| Nov 4, 2025 | Citigroup | Yigal Nochomovitz | Neutral | Maintains | $198.00 |
| Oct 17, 2025 | B of A Securities | Alec Stranahan | Buy | Maintains | $255.00 |
| Sep 15, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $240.00 |
| Aug 22, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $240.00 |
| Aug 22, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $216.00 |
| Aug 5, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $219.00 |
| Aug 5, 2025 | Citigroup | Yigal Nochomovitz | Neutral | Maintains | $166.00 |
| Jul 25, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $219.00 |
Krystal Biotech Inc. (KRYS) Competitors
The following stocks are similar to Krystal Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
KRYS
Krystal Biotech
mkt cap
7.42B
Krystal Biotech Inc. (KRYS) Financial Data
Krystal Biotech Inc. has a market capitalization of $7.23B with a P/E ratio of 36.7x. The company generates $389.13M in trailing twelve-month revenue with a 52.6% profit margin.
Revenue growth is +17.5% quarter-over-quarter, while maintaining an operating margin of +41.3% and return on equity of +18.9%.
Valuation Metrics
Market Cap
$7.23B
Enterprise Value
$6.53B
P/E Ratio
36.7x
PEG Ratio
3.1x
Price/Sales
18.9x
Growth & Margins
Revenue Growth (YoY)
+17.5%
Gross Margin
+93.8%
Operating Margin
+41.3%
Net Margin
+52.6%
EPS Growth
+13.0%
Financial Health
Cash/Price Ratio
+11.5%
Current Ratio
10.0x
Debt/Equity
0.8x
ROE
+18.9%
ROA
+8.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Krystal Biotech Inc. (KRYS) Business Model
About Krystal Biotech Inc.
What They Do
Develops gene therapy products for skin diseases.
Business Model
The company utilizes its proprietary STAR-D platform to develop and commercialize non-viral gene therapy products targeting rare dermatological conditions. By focusing on innovative gene delivery technology, Krystal Biotech aims to meet unmet medical needs and generate revenue through the sale of its therapies once approved.
Additional Information
Founded in 2016 and based in Pittsburgh, Pennsylvania, Krystal Biotech is positioned within the healthcare and biotechnology sectors, aiming to revolutionize treatments for genetic skin disorders and improve patient outcomes through advanced therapeutic options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
295
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Country
United States
IPO Year
2017
Website
www.krystalbio.comKrystal Biotech Inc. (KRYS) Latest News & Analysis
Latest News
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
20 days ago
Quick Summary
Redmile Group purchased 16,317 shares of Krystal Biotech, valued at $3.43 million. The position's quarter-end value rose by $50.33 million due to trading and price changes.
Why It Matters
Redmile Group's significant investment in Krystal Biotech and the substantial increase in position value indicate strong market confidence, potentially signaling growth prospects for the company.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
KRYS exceeded Q4 estimates with a 17% increase in Vyjuvek sales, secured over 660 U.S. reimbursements, and is advancing its gene therapy pipeline through 2026.
Why It Matters
KRYS exceeding Q4 estimates and strong Vyjuvek sales indicate robust growth potential. Securing reimbursements enhances revenue prospects, while the gene therapy pipeline extension signals long-term value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Krystal Biotech, Inc. (KRYS) held its Q4 2025 earnings call, providing updates on financial performance and strategic initiatives. Further details can be found in the full transcript.
Why It Matters
Krystal Biotech's Q4 2025 earnings call provides insights into financial performance, growth strategies, and future projections, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
25 days ago
Quick Summary
Krystal Biotech reported $107.1M in Q4 VYJUVEK revenue and $730.3M since its U.S. launch. The company has $955.9M in cash and investments and received RMAT and Fast Track designations for new treatments.
Why It Matters
Strong revenue growth and significant FDA designations boost Krystal Biotech's market position. A robust cash balance enhances financial stability, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Krystal Biotech is rated "Buy" as VYJUVEK's strong launch boosts profitability. High gross margins and promising Phase 1 data for KB407 in cystic fibrosis enhance growth potential.
Why It Matters
Krystal Biotech's strong VYJUVEK launch and promising pipeline enhance profitability and growth potential, indicating a solid investment opportunity with significant market upside.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Krystal Biotech launched the first topical gene therapy, while ARS Pharmaceuticals introduced the first needle-free treatment for anaphylaxis.
Why It Matters
Innovations in gene and needle-free therapies can drive market growth and attract investment, signaling potential for high returns and advancements in healthcare solutions.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About KRYS Stock
What is Krystal Biotech Inc.'s (KRYS) stock forecast for 2026?
Based on our analysis of 17 Wall Street analysts, Krystal Biotech Inc. (KRYS) has a median price target of $310.00. The highest price target is $371.00 and the lowest is $241.00.
Is KRYS stock a good investment in 2026?
According to current analyst ratings, KRYS has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $247.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KRYS stock?
Wall Street analysts predict KRYS stock could reach $310.00 in the next 12 months. This represents a 25.4% increase from the current price of $247.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Krystal Biotech Inc.'s business model?
The company utilizes its proprietary STAR-D platform to develop and commercialize non-viral gene therapy products targeting rare dermatological conditions. By focusing on innovative gene delivery technology, Krystal Biotech aims to meet unmet medical needs and generate revenue through the sale of its therapies once approved.
What is the highest forecasted price for KRYS Krystal Biotech Inc.?
The highest price target for KRYS is $371.00 from Yigal Nochomovitz at Citigroup, which represents a 50.0% increase from the current price of $247.26.
What is the lowest forecasted price for KRYS Krystal Biotech Inc.?
The lowest price target for KRYS is $241.00 from at , which represents a -2.5% decrease from the current price of $247.26.
What is the overall KRYS consensus from analysts for Krystal Biotech Inc.?
The overall analyst consensus for KRYS is bullish. Out of 17 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $310.00.
How accurate are KRYS stock price projections?
Stock price projections, including those for Krystal Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 14, 2026 5:01 PM UTC